Findings from a population-based prospective cohort study.
Trastuzumab deruxtecan does not necessarily require high levels of HER2 expression.
Phase 2 FIGHT trial showed biomarker selection beyond HER2.
Esophageal cancer is associated with malnutrition, and weight loss is associated with reduced survival.
The authors suggest immediately addressing cognitive deficit, regardless of severity.
Anthropometry, body fat and reproductive factors in relation to oesophageal and gastric cancer by subtype/subsite in the UK Biobank cohort.
Low genetic analysis rates at diagnosis may be result of cost concerns.
Nivolumab is the first PD-1 inhibitor to show benefit in this population and could be a new potential standard therapy.
Nivolumab plus chemotherapy has superior survival effect vs chemotherapy alone.
It is the first adjuvant therapy to show a benefit over placebo in this population.
Chemotherapy is associated with less than a year survival and significant toxicity.
Efficacy of NAC with standard surgery was already established.
Laparoscopic total gastrectomy already has been widely adopted.
Results support current recommendations of polychemotherapy, ramucirumab plus chemotherapy.
Royal Marsden study finds that microscopic colitis is an important subgroup in patients with immune checkpoint inhibitor-related diarrhoea/colitis.
Findings could help prioritize surgical procedures amidst the COVID-19 pandemic.
Trial included patients with HER2+ LA/mGC in the phase 1 component.
